Phenobarbital (Epilepsy)

Macrosomia (> 4000g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7981
R24254		 Coste (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2020 Weight at birth (≥3500 g) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 0.56 [0.33;0.96] C
excluded (control group) 		17/84   879/2,813 896 84
ref
S7809
R23145		 Coste (Phenobarbital) (Controls unexposed, NOS), 2020 Weight at birth (≥3500 g) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.50 [0.29;0.85] C 17/84   577,097/1,710,441 577,114 84
ref
S8225
R25805		 Endo (Phenobarbital) (Controls unexposed, sick), 2004 Birth weight > 4,000g throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 0.05 [0.00;6.68] C 0/10   0/1 0 10
ref
Total 2 studies 0.49 [0.29;0.82] 577,114 94
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Phenobarbital) (Controls unexposed, NOS), 2020Coste, 2020 1 0.50[0.29; 0.85]577,1148499%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Endo (Phenobarbital) (Controls unexposed, sick), 2004Endo, 2004 2 0.05[0.00; 6.68]0101%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.49[0.29; 0.82]577,114940.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Phenobarbital) (Controls unexposed, NOS; 2: Phenobarbital) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.49[0.29; 0.82]577,114940%NACoste (Phenobarbital) (Controls unexposed, NOS), 2020 Endo (Phenobarbital) (Controls unexposed, sick), 2004 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.50[0.29; 0.85]577,11484 -NACoste (Phenobarbital) (Controls unexposed, NOS), 2020 1 unexposed, sickunexposed, sick 0.05[0.00; 6.68]-10 -NAEndo (Phenobarbital) (Controls unexposed, sick), 2004 1 Tags Adjustment   - No  - No 0.49[0.29; 0.82]577,114940%NACoste (Phenobarbital) (Controls unexposed, NOS), 2020 Endo (Phenobarbital) (Controls unexposed, sick), 2004 2 All studiesAll studies 0.49[0.29; 0.82]577,114940%NACoste (Phenobarbital) (Controls unexposed, NOS), 2020 Endo (Phenobarbital) (Controls unexposed, sick), 2004 20.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 7981

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale0.50[0.29; 0.85]577,11484 -NACoste (Phenobarbital) (Controls unexposed, NOS), 2020 1 unexposed, sick controlsunexposed, sick controls Out of scale0.05[0.00; 6.68]-10 -NAEndo (Phenobarbital) (Controls unexposed, sick), 2004 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.56[0.33; 0.96]89684 -NACoste (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2020 10.510.01.0